Anzeige
Erschienen in:
08.12.2017 | Original Article
Incongruence in treatment decision making is associated with lower health-related quality of life among prostate cancer survivors: results from the PiCTure study
Erschienen in: Supportive Care in Cancer | Ausgabe 5/2018
Einloggen, um Zugang zu erhaltenAbstract
Purpose
We investigated associations between treatment decision making (TDM) and global health-related-quality-of-life (gHRQoL) among prostate cancer (PCa) survivors.
Methods
Postal questionnaires were sent to 6559 PCa survivors 2–18 years post-diagnosis, identified through population-based cancer registries in Ireland. The Control Preference Scale was used to investigate respondents’ ‘actual’ and ‘preferred’ role in TDM. The TDM experience was considered ‘congruent’ when actual and preferred roles matched and ‘incongruent’ otherwise. The EORTC QLQ-C30 was used to measure gHRQoL. Multivariate linear regression was employed to investigate associations between (i) actual role in TDM, (ii) congruence in TDM, and gHRQoL.
Results
The response rate was 54% (n = 3348). The percentages of men whose actual role in TDM was active, shared or passive were 36, 33 and 31%, respectively. Congruence between actual and preferred roles in TDM was 58%. Actual role in TDM was not associated with gHRQoL. In multivariate analysis, after adjusting for socio-demographic and clinical factors, survivors whose TDM experience was incongruent had significantly lower gHRQoL than those who had a congruent experience (− 2.25 95%CI − 4.09, − 0.42; p = 0.008). This effect was most pronounced among survivors who had more involvement in the TDM than they preferred (− 2.69 95%CI − 4.74, − 0.63; p = 0.010).
Conclusions
Less than 6 in 10 PCa survivors experienced congruence between their actual and preferred roles in TDM. Having an incongruent TDM experience was associated with lower gHRQoL among survivors. These findings suggest that involving patients in TDM to the degree to which they want to be involved may help improve PCa survivors’ gHRQoL.